EnteroBiotix article features in Medicine Maker

EnteroBiotix in the news
Written By James McIlroy

Thank you to Modern Medicine for publishing this informative article on the clinical benefits of modulating the microbiome authored by our CEO Dr James McIlroy.

In the article Dr McIlroy discusses the clinical benefits of modulating the microbiome, which are leading to new medical products and inspiring a behavioral shift in gut health. Sharing the wonders of manipulating our microbial passengers.

James McIlroy
Previous

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
Next

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics